The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis

References

• NavadaSLaiPSchwartzAGKalemkerianGPTemporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) databaseJ Clin Oncol (Meeting Abstracts)200624Suppl 18 Abstract 7082
   Web of Science ®Google Scholar
• ZarogoulidisKLatsiosDPorpodisKZarogoulidisPDarwicheKAntoniouNHohenforst-SchmidtWEleftheriadouEBoutsikouEKontakiotisTNew dilemmas in small-cell lung cancer TNM clinical stagingOnco Targets Ther2013653954723700372
   PubMed Web of Science ®Google Scholar
• ChengSEvansWKStys-NormanDShepherdFALung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based CareChemotherapy for relapsed small cell lung cancer: a systematic review and practice guidelineJ Thorac Oncol20072434835417409809
   PubMed Web of Science ®Google Scholar
• HurwitzJLMcCoyFScullinPFennellDANew advances in the second-line treatment of small cell lung cancerOncologist2009141098699419819917
   PubMed Web of Science ®Google Scholar
• PostmusPEBerendsenHHvan ZandwijkNSplinterTABurghoutsJTBakkerWRetreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapyEur J Cancer Clin Oncol1987239140914112824211
   PubMedGoogle Scholar
• KairaKSunagaNTomizawaYA phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancerLung Cancer20106919910419853960
   PubMed Web of Science ®Google Scholar
• JoosGSchallierDPinsonPSterckxMVan MeerbeeckJPPaclitaxel (PTX) as second line treatment in patients (pts) with small cell lung cancer (SCLC) refractory to carboplatin – etoposide: a multicenter phase II studyJ Clin Oncol (Meeting Abstracts)200422Suppl 14 Abstract 7211
   Web of Science ®Google Scholar
• SmitEFFokkemaEBiesmaBGroenHJSnoekWPostmusPEA phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancerBr J Cancer19987723473519461009
   PubMed Web of Science ®Google Scholar
• HongJJungMKimYJPhase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancerCancer Chemother Pharmacol201269121522021691745
   PubMed Web of Science ®Google Scholar
• ZarogoulidisKZiogasEBoutsikouEImmunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized studyDrug Des Devel Ther20137611617
   PubMed Web of Science ®Google Scholar
• GroenHJFokkemaEBiesmaBPaclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant scheduleJ Clin Oncol199917392793210071286
   PubMed Web of Science ®Google Scholar
• MurrayNTurrisiAT3rdA review of first-line treatment for small-cell lung cancerJ Thorac Oncol20061327027817409868
   PubMed Web of Science ®Google Scholar
• SkarlosDVSamantasEKosmidisPRandomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group studyAnn Oncol1994576016077993835
   PubMed Web of Science ®Google Scholar
• NairBSBhanderiVJafriSHCurrent and emerging pharmacotherapies for the treatment of relapsed small cell lung cancerClin Med Insights Oncol2011522323421836818
   PubMedGoogle Scholar
• PopatSO’BrienMChemotherapy strategies in the treatment of small cell lung cancerAnticancer Drugs200516436137215746572
   PubMed Web of Science ®Google Scholar
• KallianosARaptiAZarogoulidisPTherapeutic procedure in small cell lung cancerJ Thorac Dis20135S4S420S42424102016
   PubMed Web of Science ®Google Scholar
• SundstrømSBremnesRMKaasaSAasebøUAamdalSNorwegian Lung Cancer Study GroupSecond-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen)Lung Cancer200548225126115829326
   PubMed Web of Science ®Google Scholar
• KimYHGotoKYo hKPerformance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapyCancer200811392518252318780323
   PubMed Web of Science ®Google Scholar
• AgelakiSHatzidakiDKotsakisANon-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research GroupOncology2010783–422923620523083
   PubMed Web of Science ®Google Scholar
• FarsalinosKERomagnaGTsiaprasDKyrzopoulosSVoudrisVEvaluating nicotine levels selection and patterns of electronic cigarette use in a group of “vapers” who had achieved complete substitution of smokingSubst Abuse2013713914624049448
   PubMedGoogle Scholar
• PlanchardDLe PéchouxCSmall cell lung cancer: new clinical recommendations and current status of biomarker assessmentEur J Cancer201147Suppl 3S272S28321943984
   PubMed Web of Science ®Google Scholar
• SpiroSGSouhamiRLGeddesDMDuration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trialBr J Cancer19895945785832540788
   PubMed Web of Science ®Google Scholar
• RossiAMartelliODi MaioMTreatment of patients with small-cell lung cancer: from meta-analyses to clinical practiceCancer Treat Rev201339549850623084098
   PubMed Web of Science ®Google Scholar
• von PawelJSchillerJHShepherdFATopotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancerJ Clin Oncol199917265866710080612
   PubMed Web of Science ®Google Scholar
• EckardtJRvon PawelJPujolJLPhase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancerJ Clin Oncol200725152086209217513814
   PubMed Web of Science ®Google Scholar
• FukuokaMFuruseKSaijoNRandomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancerJ Natl Cancer Inst199183128558611648142
   PubMedGoogle Scholar
• ShepherdFAEvansWKMacCormickRFeldRYa uJCCyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancerCancer Treat Rep198771109419442820571
   PubMedGoogle Scholar
• RothBJJohnsonDHEinhornLHRandomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study GroupJ Clin Oncol19921022822911310103
   PubMed Web of Science ®Google Scholar